If you’re a federal employee and have questions about continuing coverage, please speak to your Patient Benefits Specialist and visit our insurance page here: virginiacancerspecialists.com/insurance/.
A monoclonal antibody (MoAb) directed against the human epidermal growth factor receptor 2 (HER2; ERBB2) labeled with iodine I 131 using the residualizing radio-iodinating reagent N-succinimidyl 4-guanidinomethyl 3-iodobenzoate (SGMIB), with potential radiotherapeutic and radioimaging activities upon positron emission tomography (PET). Upon administration of iodine I 131 SGMIB-anti-HER2 VHH1, the HER2 MoAb moiety selectively targets and binds to HER2-expressing tumor cells. Upon PET imaging, tumor cells can be visualized. In addition, the iodine I 131 moiety of VHH1 selectively delivers a cytotoxic dose of iodine I 131 to the tumor cells. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types. SGMIB improves tumor retention of radioactivity and decreases exocytosis. Check for active clinical trials using this agent. (NCI Thesaurus)
Related Posts
Recent Posts
